330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1818927544339005440 |
|---|---|
| author | Mohammad Zaidi Yuchen Zhang Kavita Dhodapkar Madhav Dhodapkar Gregory Lesinski Matthew Farren Christina Wu Rafi Ahmed Cameron Herting Deon Doxie Michael Ware Olatunji Alese Walid Shaib Mehmet Akce Amanda Ruggieri Juan Sarmiento Shishir Maithel Bassel El-rayes |
| author_facet | Mohammad Zaidi Yuchen Zhang Kavita Dhodapkar Madhav Dhodapkar Gregory Lesinski Matthew Farren Christina Wu Rafi Ahmed Cameron Herting Deon Doxie Michael Ware Olatunji Alese Walid Shaib Mehmet Akce Amanda Ruggieri Juan Sarmiento Shishir Maithel Bassel El-rayes |
| author_sort | Mohammad Zaidi |
| collection | DOAJ |
| first_indexed | 2024-12-20T03:14:42Z |
| format | Article |
| id | doaj.art-bec310594f32496d883a30fa5029bf28 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-20T03:14:42Z |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-bec310594f32496d883a30fa5029bf282022-12-21T19:55:22ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0330330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignanciesMohammad Zaidi0Yuchen Zhang1Kavita Dhodapkar2Madhav Dhodapkar3Gregory Lesinski4Matthew Farren5Christina Wu6Rafi Ahmed7Cameron Herting8Deon Doxie9Michael Ware10Olatunji Alese11Walid Shaib12Mehmet Akce13Amanda Ruggieri14Juan Sarmiento15Shishir Maithel16Bassel El-rayes171Winship Cancer Institute of Emory University, Decatur, GA, USA2Xi’an Jiaotong University, Shaanxi, China3Emory University School of Medicine, Atlanta, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA4Emory University, Atlanta, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA3Emory University School of Medicine, Atlanta, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA1Winship Cancer Institute of Emory University, Decatur, GA, USA |
| spellingShingle | Mohammad Zaidi Yuchen Zhang Kavita Dhodapkar Madhav Dhodapkar Gregory Lesinski Matthew Farren Christina Wu Rafi Ahmed Cameron Herting Deon Doxie Michael Ware Olatunji Alese Walid Shaib Mehmet Akce Amanda Ruggieri Juan Sarmiento Shishir Maithel Bassel El-rayes 330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies Journal for ImmunoTherapy of Cancer |
| title | 330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies |
| title_full | 330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies |
| title_fullStr | 330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies |
| title_full_unstemmed | 330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies |
| title_short | 330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies |
| title_sort | 330 investigating the clinical safety efficacy and immune modulation of combined xl888 and pembrolizumab in metastatic gastrointestinal malignancies |
| work_keys_str_mv | AT mohammadzaidi 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT yuchenzhang 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT kavitadhodapkar 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT madhavdhodapkar 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT gregorylesinski 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT matthewfarren 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT christinawu 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT rafiahmed 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT cameronherting 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT deondoxie 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT michaelware 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT olatunjialese 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT walidshaib 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT mehmetakce 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT amandaruggieri 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT juansarmiento 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT shishirmaithel 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies AT basselelrayes 330investigatingtheclinicalsafetyefficacyandimmunemodulationofcombinedxl888andpembrolizumabinmetastaticgastrointestinalmalignancies |